The RaDAR Program provides comprehensive drug testing data to 13 states and territories across the U.S. In total, more than 10,000 samples have been analyzed since the RaDAR Program began in October 2022, and notably, more than 6,500 samples were analyzed in Fiscal Year 2024 alone. The RaDAR Program’s analysis and reports provide its RaDAR Participants with chemical compound data that law enforcement, harm reduction organizations, healthcare providers, and policymakers can use to develop a more effective strategy in reducing fatalities and mitigating the devastating impact of the opioid crisis on communities.
THE TEAM: